SCHEMBL2904863

SCHEMBL2904863

CN1CCC(N(C)C(c2ccccc2)c2c[nH]nc2-c2ccccc2F)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 3/20 0.34
SLC6A2 P23975 4/20 0.33
CHRM3 P20309 1/20 0.33
POLB P06746 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MCHR1 Q99705 2/20 0.32
CHRM1 P11229 2/20 0.32
SLC6A4 P31645 1/20 0.32
CHRM2 P08172 1/20 0.32
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
CYP2D6 P10635 1/20 0.32
DRD1 P21728 1/20 0.32
ADRA1A P35348 1/20 0.32
OPRM1 P35372 1/20 0.32
DRD3 P35462 1/20 0.32
SLC6A3 Q01959 1/20 0.32
KCNH2 Q12809 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902618 0.87 MCHR1 (0.38) CCR5SLC6A2POLBKDM4EMCHR1
SCHEMBL2902344 0.82 CCR5 (0.36) CCR5SLC6A2POLBKDM4EMCHR1
SCHEMBL2905013 0.78 MEN1 (0.37) KDM4EMEN1KMT2A
SCHEMBL2904868 0.76 CHRM3 (0.37) CHRM3KDM4EMEN1KMT2A
SCHEMBL2905202 0.75 CHRM1 (0.36) SLC6A2MCHR1CHRM1SLC6A4HRH3
SCHEMBL2905437 0.74 MEN1 (0.34) KDM4EOPRM1MEN1KMT2A
SCHEMBL2907391 0.73 OPRM1 (0.50) SLC6A2CHRM3KDM4ECHRM1SLC6A4
SCHEMBL2904631 0.71 MCHR1 (0.40) POLBKDM4EMCHR1HTR1AOPRM1
SCHEMBL2902536 0.69 OPRK1 (0.36) KDM4EOPRM1MEN1KMT2A
SCHEMBL2908495 0.68 MCHR1 (0.35) POLBKDM4EMCHR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed
CN-1768043-A 1,3,4-substituted pyrazoles for use as 5-ht receptor antagonists in the treatment of psychoses and neurological disorders. MERCK PATENT GMBH (DE) 2006-05-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A CCR5 1516/4885SLC6A2 125/4885CHRM3 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.